AN2 Therapeutics (ANTX)
(Delayed Data from NSDQ)
$2.40 USD
0.00 (0.00%)
Updated May 1, 2024 04:00 PM ET
After-Market: $2.40 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
AN2 Therapeutics, Inc. (ANTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.00 | $7.00 | $5.00 | 150.00% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for AN2 Therapeutics, Inc. comes to $6.00. The forecasts range from a low of $5.00 to a high of $7.00. The average price target represents an increase of 150% from the last closing price of $2.40.
Analyst Price Targets (3 )
Broker Rating
AN2 Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 2.20 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, two are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 40%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 1 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 4 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.20 | 2.20 | 2.20 | 2.60 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/2/2024 | JMP Securities | Roy Buchanan | Hold | Strong Buy |
2/13/2024 | SVB Securities | Joseph P Schwartz | Hold | Hold |
2/12/2024 | Evercore Partners | Liisa A Bayko | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.20 |
ABR (Last week) | 2.20 |
# of Recs in ABR | 5 |
Average Target Price | $6.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 73 of 252 |
Current Quarter EPS Est: | -0.61 |